EVMN
Evommune, Inc.
NYSE · Healthcare · Biotechnology · US
$12.27
+2.25%Year over year
Reported trailing growth
- Revenue
- +233.3%
- EBITDA
- -31.1%
- EBIT
- -19.5%
- EPS
- +14.5%
- Free cash flow
- +8.0%
- Operating cash flow
- +8.6%
Forward estimates
Based on analyst estimates
- Revenue
- -58.3%
- EBITDA
- +37.7%
- EPS
- -25.9%
Three-year CAGR
- Revenue
- +61.2%
- EBITDA
- -3.0%
- EBIT
- -15.8%
- Net income
- -3.1%
- EPS
- +4.0%
- Free cash flow
- -31.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026